GENEMEDICS APP
GENEMEDICS NUTRITION
Melatonin is a hormone that is naturally produced by the pineal gland. It is mainly secreted at night during sleep. This hormone plays a significant role in the sleep-wake cycle of animals and humans. As a dietary supplement, melatonin is often used for the treatment of sleep problems such as insomnia caused by shift work or jet lag. An overwhelming body of clinical evidence suggests that melatonin is not just beneficial in maintaining a good sleep pattern but also in different aspects of health.
There are a lot of high-quality studies supporting the primary benefit of melatonin:
Studies show that melatonin can help protect against heart disease:
Evidence found that melatonin also has anti-cancer properties:
Melatonin has also been found to be beneficial in overweight and obese patients:
Melatonin can also help strengthen the immune system:
Studies suggest that melatonin has anti-hypertensive properties:
Evidence also supports the beneficial effects of melatonin on brain health:
Melatonin also has mood-boosting properties:
Supplementation with melatonin has been found to improve bone health:
Melatonin is also essential for optimum eye health:
Studies show that melatonin has anti-aging effects on the skin:
Evidence also suggests that melatonin has regenerative properties:
Melatonin is also beneficial for people with diabetes and elevated blood sugar levels:
Xie Z, Chen F, Li WA, Geng X, Li C, Meng X, Feng Y, Liu W, Yu F. A review of sleep disorders and melatonin. Neurol Res. 2017 Jun;39(6):559-565. doi: 10.1080/01616412.2017.1315864. Epub 2017 May 1. PMID: 28460563.
A review of sleep disorders and melatonin
The review article “A review of sleep disorders and melatonin” by Xie Z, Chen F, Li WA, Geng X, Li C, Meng X, Feng Y, Liu W, Yu F, published in Neurol Res in 2017, provides an overview of sleep disorders and the role of melatonin in managing them. It discusses the relationship between melatonin and sleep regulation and its potential therapeutic applications in sleep-related conditions.
Click the link for more details: https://pubmed.ncbi.nlm.nih.gov/28460563/
Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br J Pharmacol. 2018;175(16):3190-3199. doi:10.1111/bph.14116.
New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation
The review article “New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation” by Zisapel N, published in the British Journal of Pharmacology in 2018, provides updated insights into the role of melatonin in human sleep and circadian rhythms. It discusses the regulation of sleep-wake cycles and highlights the evolving understanding of melatonin’s functions in maintaining healthy sleep patterns.
For more details: https://pubmed.ncbi.nlm.nih.gov/29464773/
Ferracioli-Oda E, Qawasmi A, Bloch MH. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013 May 17;8(5):e63773. doi: 10.1371/journal.pone.0063773. PMID: 23691095; PMCID: PMC3656905.
Melatonin for the treatment of primary sleep disorders
The meta-analysis “Melatonin for the treatment of primary sleep disorders” by Ferracioli-Oda E, Qawasmi A, Bloch MH, published in PLoS One in 2013, evaluates the effectiveness of melatonin in treating primary sleep disorders. The study found that melatonin supplementation was associated with improvements in sleep onset latency and sleep quality, making it a potential option for managing sleep-related conditions.
For more details: https://pubmed.ncbi.nlm.nih.gov/23691095/
Tordjman S, Chokron S, Delorme R, et al. Melatonin: Pharmacology, Functions and Therapeutic Benefits. Curr Neuropharmacol. 2017;15(3):434-443. doi:10.2174/1570159X14666161228122115.
Melatonin: Pharmacology, Functions and Therapeutic Benefits
The review article “Melatonin: Pharmacology, Functions, and Therapeutic Benefits” by Tordjman et al., published in Current Neuropharmacology in 2017, provides an overview of melatonin’s pharmacology, functions, and potential therapeutic benefits. It discusses melatonin’s role in regulating circadian rhythms, its antioxidant properties, and its potential applications in various medical conditions.
Click this link for the full article: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405617/
Auld F, Maschauer EL, Morrison I, Skene DJ, Riha RL. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Med Rev. 2017 Aug;34:10-22. doi: 10.1016/j.smrv.2016.06.005. Epub 2016 Jul 20. PMID: 28648359.
Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders
The review article “Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders” by Auld et al., published in Sleep Medicine Reviews in 2017, presents evidence supporting the efficacy of melatonin in treating primary sleep disorders in adults. The study highlights melatonin’s potential benefits in improving sleep quality and regulating sleep patterns.
For more details: https://pubmed.ncbi.nlm.nih.gov/28648359/
Kostoglou-Athanassiou I. Therapeutic applications of melatonin. Ther Adv Endocrinol Metab. 2013;4(1):13-24. doi:10.1177/2042018813476084.
Therapeutic applications of melatonin
The review article “Therapeutic applications of melatonin” by Kostoglou-Athanassiou, published in Therapeutic Advances in Endocrinology and Metabolism in 2013, explores the therapeutic uses of melatonin. It discusses melatonin’s potential applications in various medical conditions and highlights its role in regulating circadian rhythms and sleep-wake cycles.
For more details: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3557236/
Gray C, Ryce A. Melatonin for the Treatment of Insomnia: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Feb 22. Available from: https://www.ncbi.nlm.nih.gov/books/NBK544670/
Melatonin for the Treatment of Insomnia
The document “Melatonin for the Treatment of Insomnia: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines” is a review conducted by the Canadian Agency for Drugs and Technologies in Health in 2019. It assesses the clinical effectiveness and cost-effectiveness of melatonin in treating insomnia. The document also provides insights into relevant guidelines and recommendations regarding the use of melatonin for insomnia management. For detailed information, you can access the full document.
For more information: https://www.ncbi.nlm.nih.gov/books/NBK544670/
Jan JE, Espezel H, Appleton RE. The treatment of sleep disorders with melatonin. Dev Med Child Neurol. 1994 Feb;36(2):97-107. doi: 10.1111/j.1469-8749.1994.tb11818.x. PMID: 8132132.
Developmental Medicine and Child Neurology
The study by Jan et al. in “Developmental Medicine and Child Neurology” (1994) explores the use of melatonin in treating sleep disorders, particularly in children. It discusses the potential benefits of melatonin supplementation for improving sleep patterns in individuals with various sleep disturbances. The study highlights its therapeutic potential in managing sleep-related issues.
For more information: https://pubmed.ncbi.nlm.nih.gov/8132132/
Sun H, Gusdon AM, Qu S. Effects of melatonin on cardiovascular diseases: progress in the past year. Curr Opin Lipidol. 2016;27(4):408-413. doi:10.1097/MOL.0000000000000314.
Effects of melatonin on cardiovascular diseases: progress in the past year
The review article “Effects of melatonin on cardiovascular diseases: progress in the past year” by Sun et al. (2016) provides an overview of recent advancements in understanding the impact of melatonin on cardiovascular diseases. It discusses the potential therapeutic effects of melatonin in mitigating cardiovascular conditions and highlights progress made in the field within the past year.
For more information: https://journals.lww.com/co-lipidology/Abstract/2016/08000/Effects_of_melatonin_on_cardiovascular_diseases_.5.aspx
Sewerynek E. Melatonin and the cardiovascular system. Neuro Endocrinol Lett. 2002 Apr;23 Suppl 1:79-83. PMID: 12019357.
Melatonin and the cardiovascular system
The article by Sewerynek (2002) explores the role of melatonin in the cardiovascular system. It discusses melatonin’s potential impact on cardiovascular functions and its relevance to overall health.
For more information: https://pubmed.ncbi.nlm.nih.gov/12019357/
Pandi-Perumal SR, BaHammam AS, Ojike NI, Akinseye OA, Kendzerska T, Buttoo K, Dhandapany PS, Brown GM, Cardinali DP. Melatonin and Human Cardiovascular Disease. J Cardiovasc Pharmacol Ther. 2017 Mar;22(2):122-132. doi: 10.1177/1074248416660622. Epub 2016 Jul 27. PMID: 27450357.
Melatonin and Human Cardiovascular Disease
The study by Pandi-Perumal et al. (2017) examines the role of melatonin in human cardiovascular disease. It discusses the potential therapeutic effects of melatonin in managing cardiovascular conditions. The research highlights the impact of melatonin on various aspects of cardiovascular health and provides insights into its potential benefits.
For more information: https://pubmed.ncbi.nlm.nih.gov/27450357/
Nduhirabandi F, Maarman GJ. Melatonin in Heart Failure: A Promising Therapeutic Strategy? Molecules. 2018;23(7):1819. Published 2018 Jul 22. doi:10.3390/molecules23071819.
Melatonin in Heart Failure: A Promising Therapeutic Strategy?
The article by Nduhirabandi and Maarman (2018) explores the potential therapeutic use of melatonin in heart failure. It discusses the promising aspects of melatonin as a strategy for managing heart failure. The study delves into the potential benefits and mechanisms of melatonin in addressing cardiovascular issues.
For more information: https://www.mdpi.com/1420-3049/23/7/1819
Reiter RJ, Tan DX, Paredes SD, Fuentes-Broto L. Beneficial effects of melatonin in cardiovascular disease. Ann Med. 2010 May 6;42(4):276-85. doi: 10.3109/07853890903485748. PMID: 20455793.
Beneficial effects of melatonin in cardiovascular disease
The review article by Reiter et al. (2010) discusses the beneficial effects of melatonin in cardiovascular disease. It explores the potential advantages of melatonin as a therapeutic agent for managing cardiovascular conditions. The study highlights melatonin’s role in mitigating oxidative stress and inflammation, which are key factors in cardiovascular disease.
For more information: https://pubmed.ncbi.nlm.nih.gov/20455793/
Reiter RJ, Rosales-Corral SA, Tan DX, et al. Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis. Int J Mol Sci. 2017;18(4):843. Published 2017 Apr 17. doi:10.3390/ijms18040843.
Melatonin, a Full Service Anti-Cancer Agent
The article by Reiter et al. (2017) highlights melatonin’s role as a comprehensive anti-cancer agent. It discusses its potential in inhibiting the initiation, progression, and metastasis of cancer. Melatonin’s multifaceted properties make it a promising candidate for cancer prevention and treatment.
For more details on this article, click on https://www.mdpi.com/1422-0067/18/4/843
Li Y, Li S, Zhou Y, et al. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017;8(24):39896-39921. doi:10.18632/oncotarget.16379.
Melatonin for the prevention and treatment of cancer
The article by Li et al. (2017) provides a comprehensive overview of melatonin’s potential in cancer prevention and treatment. It highlights melatonin’s multifaceted role in inhibiting tumor growth, angiogenesis, and metastasis while enhancing the body’s immune response against cancer cells. The review discusses the scientific evidence supporting melatonin’s effectiveness as an adjuvant therapy in various types of cancer.
For more details on this article click on https://www.oncotarget.com/article/16379/text/
Cutando A, López-Valverde A, Arias-Santiago S, DE Vicente J, DE Diego RG. Role of melatonin in cancer treatment. Anticancer Res. 2012 Jul;32(7):2747-53. PMID: 22753734.
Role of melatonin in cancer treatment
The article by Cutando et al. (2012) discusses the role of melatonin in cancer treatment. It explores melatonin’s potential as an adjuvant therapy in cancer management. The study highlights its impact on tumor growth inhibition, anti-angiogenic effects, and enhancement of chemotherapy and radiotherapy outcomes.
For more details on this article, click on https://pubmed.ncbi.nlm.nih.gov/22753734/
Wang Y, Wang P, Zheng X, Du X. Therapeutic strategies of melatonin in cancer patients: a systematic review and meta-analysis. Onco Targets Ther. 2018;11:7895-7908. Published 2018 Nov 8. doi:10.2147/OTT.S174100.
Therapeutic strategies of melatonin in cancer patients
The systematic review and meta-analysis by Wang et al. (2018) focus on therapeutic strategies involving melatonin in cancer patients. It provides a comprehensive analysis of the available literature to assess the effectiveness of melatonin as an adjunctive treatment for cancer. The study covers various aspects, including melatonin’s impact on tumor size reduction, improved survival rates, and reduced side effects of cancer therapies.
Read the full article at https://www.dovepress.com/therapeutic-strategies-of-melatonin-in-cancer-patients-a-systematic-re-peer-reviewed-fulltext-article-OTT
Jung B, Ahmad N. Melatonin in cancer management: progress and promise. Cancer Res. 2006 Oct 15;66(20):9789-93. doi: 10.1158/0008-5472.CAN-06-1776. PMID: 17047036.
Melatonin in cancer management: progress and promise
The 2006 study “Melatonin in Cancer Management: Progress and Promise” by Jung B and Ahmad N examines melatonin’s role in cancer treatment. It suggests that melatonin can enhance chemotherapy efficacy and reduce its side effects. The hormone shows chemopreventive, oncostatic, and tumor-inhibitory effects in various studies. Additionally, melatonin affects tumor development and progression by influencing angiogenesis, cell proliferation, and other pathways. The study indicates melatonin’s potential as a therapeutic and preventative agent in oncology.
For the full article, please refer to this link: https://pubmed.ncbi.nlm.nih.gov/17047036/
Szewczyk-Golec K, Rajewski P, Gackowski M, et al. Melatonin Supplementation Lowers Oxidative Stress and Regulates Adipokines in Obese Patients on a Calorie-Restricted Diet. Oxid Med Cell Longev. 2017;2017:8494107. doi:10.1155/2017/8494107.
Melatonin Supplementation Lowers Oxidative Stress and Regulates Adipokines in Obese Patients on a Calorie-Restricted Diet
The 2017 study “Melatonin Supplementation Lowers Oxidative Stress and Regulates Adipokines in Obese Patients on a Calorie-Restricted Diet” by Szewczyk-Golec K, Rajewski P, Gackowski M, et al., investigates the impact of melatonin on obese individuals adhering to a calorie-restricted diet. This study was conducted in response to the growing global health issue of obesity and the observed correlation between melatonin deficiency and obesity. The primary objective was to evaluate the effect of melatonin supplementation on oxidative stress and adipokine levels in the context of obesity management.
Key findings from the study include the observation that melatonin supplementation facilitated body weight reduction, improved the body’s antioxidant defense mechanisms, and regulated adipokine secretion in obese patients. Adipokines are cytokines produced mainly by adipose tissue, and they play a crucial role in metabolic processes. The regulation of these adipokines is essential for managing metabolic diseases like obesity. These results strongly suggest that melatonin should be considered as a potential component in obesity management strategies.
In summary, the study provides evidence that melatonin supplementation can be beneficial in reducing oxidative stress and regulating important hormones related to fat metabolism in obese patients, especially when combined with a calorie-restricted diet. This research contributes to the understanding of melatonin’s role not just in sleep regulation but also in metabolic processes and obesity management.
For more details, you can refer to the full article available at this link:https://pubmed.ncbi.nlm.nih.gov/29142618/
Walecka-Kapica E, Klupińska G, Chojnacki J, Tomaszewska-Warda K, Błońska A, Chojnacki C. The effect of melatonin supplementation on the quality of sleep and weight status in postmenopausal women. Prz Menopauzalny. 2014 Dec;13(6):334-8. doi: 10.5114/pm.2014.47986. Epub 2014 Dec 30. PMID: 26327875; PMCID: PMC4352910.
The effect of melatonin supplementation on the quality of sleep and weight status in postmenopausal women
The 2014 study “The effect of melatonin supplementation on the quality of sleep and weight status in postmenopausal women” by Walecka-Kapica E, Klupińska G, Chojnacki J, and colleagues focused on the impact of melatonin supplementation on postmenopausal women’s nutritional status. The study involved 56 women aged 51-65 years and an additional 25 healthy women aged 27-36 years. It aimed to assess the emotional state of participants using the Hamilton Depression Rating Scale, the quality of sleep using the Insomnia Severity Index, and calculated body mass index (BMI) and waist-hip ratio (WHR).
The participants were divided into three groups: a control group of 25 women with normal body weight, 26 postmenopausal women with normal body weight, and 30 postmenopausal women with high body weight. For those in the second and third groups, the study involved routine laboratory tests, including assessments of thyroid-stimulating hormone, estradiol, prolactin, follicle-stimulating hormone levels, and the concentration of 6-hydroxy melatonin sulphate in day/night urine fractions. Initially, these women were put on a liquid diet of 1800 kcal, followed by a balanced diet of 1500 kcal and a recommendation for 5 mg of melatonin administration. Follow-up examinations were conducted after 4, 8, 12, 16, 20, and 24 weeks.
The results indicated that patients in groups II and III exhibited similar mild levels of anxiety and depression, along with a significant degree of sleep disorders. Notably, lower urinary 6-HMS excretion was observed at night in group III. A negative correlation was found between urinary 6-HMS excretion and the degree of sleep disorders in both groups. After 24 weeks, there was a statistically significant improvement in the quality of sleep. Additionally, a negative correlation was observed between urinary 6-HMS excretion and BMI. The study concluded that melatonin supplementation contributed to body weight reduction in postmenopausal women.
For more information, you can access the full article via this link: https://pubmed.ncbi.nlm.nih.gov/26327875/
Mostafavi SA, Akhondzadeh S, Mohammadi MR, Keshtkar AA, Hosseini S, Eshraghian MR, Motlagh TA, Alipour R, Keshavarz SA. Role of Melatonin in Body Weight: A Systematic Review and Meta-Analysis. Curr Pharm Des. 2017;23(23):3445-3452. doi: 10.2174/1381612822666161129145618. PMID: 27897121.
The 2017 systematic review and meta-analysis “Role of Melatonin in Body Weight” by Mostafavi SA, Akhondzadeh S, Mohammadi MR, et al., investigated the effects of melatonin on body weight in human subjects. The study involved a comprehensive search and included seven clinical trials with a total of 244 patients. The results, based on evaluating the standardized mean difference, indicated that none of the studies found a strong and significant effect of melatonin on body weight. However, some reported minor decreasing or increasing effects. The analysis concluded that melatonin might slightly reduce the weight gain effect of standard treatments, and this effect seemed more pronounced in children and adolescents. The study proposes a hypothesis about melatonin’s buffering role in body weight fluctuations
For more detailed information, you can access the full article here: https://pubmed.ncbi.nlm.nih.gov/27897121/
de Farias TDSM, Cruz MM, de Sa RCDC, et al. Melatonin Supplementation Decreases Hypertrophic Obesity and Inflammation Induced by High-Fat Diet in Mice. Front Endocrinol (Lausanne). 2019;10:750. Published 2019 Nov 5. doi:10.3389/fendo.2019.00750.
Melatonin Supplementation Decreases Hypertrophic Obesity and Inflammation Induced by High-Fat Diet in Mice
The 2019 study “Melatonin Supplementation Decreases Hypertrophic Obesity and Inflammation Induced by High-Fat Diet in Mice” by de Farias TDSM, Cruz MM, et al., aimed to assess the effectiveness of melatonin in combating obesity-related disorders. In this study, 8-week-old male C57BL/6 mice induced to obesity by a high-fat diet were treated with melatonin for 10 weeks. The results demonstrated that melatonin supplementation attenuated serum triglyceride levels, total and LDL cholesterol, and prevented body mass gain. This was achieved by decreasing lipogenesis rate and increasing lipolytic capacity in white adipocytes. Additionally, melatonin supplementation reduced the formation of crown-like structures (indicative of inflammation) and decreased the expression of inflammation-related factors like leptin and MCP1. These findings suggest that melatonin can be a potential therapeutic agent to attenuate metabolic and inflammatory disorders triggered by obesity.
For more details: https://pubmed.ncbi.nlm.nih.gov/31749764/
Montalbano G, Mania M, Abbate F, Navarra M, Guerrera MC, Laura R, Vega JA, Levanti M, Germanà A. Melatonin treatment suppresses appetite genes and improves adipose tissue plasticity in diet-induced obese zebrafish. Endocrine. 2018 Nov;62(2):381-393. doi: 10.1007/s12020-018-1653-x. Epub 2018 Jun 20. PMID: 29926348.
Melatonin treatment suppresses appetite genes and improves adipose tissue plasticity in diet-induced obese zebrafish. Endocrine
The 2018 study by Montalbano, Mania, et al. titled “Melatonin treatment suppresses appetite genes and improves adipose tissue plasticity in diet-induced obese zebrafish” focused on the impact of melatonin in controlling obesity. The study involved 56 adult male zebrafish divided into four dietary groups, including control and overfed groups, both with and without melatonin treatment. The treatment lasted 5 weeks, and the study analyzed the expression levels of appetite-related genes and the morphology of fat depots. Results showed that melatonin supplementation helped in mobilizing fat stores, increasing basal metabolism, and thus preventing excess fat accumulation. It influenced both anorexigenic and orexigenic signals, leading to the conclusion that melatonin treatment has anti-obesity protective effects, evidenced by weight loss and stabilized weight gain in the zebrafish model.
For more details, the full article can be accessed here: https://pubmed.ncbi.nlm.nih.gov/29926348/
Srinivasan V, Maestroni GJ, Cardinali DP, Esquifino AI, Perumal SR, Miller SC. Melatonin, immune function and aging. Immun Ageing. 2005;2:17. Published 2005 Nov 29. doi:10.1186/1742-4933-2-17.
Melatonin, immune function and aging. Immun Ageing
The 2005 study “Melatonin, Immune Function and Aging” by Srinivasan V, Maestroni GJ, et al., explores the relationship between aging, immune function decline (immunosenescence), and melatonin. Aging is associated with weakened immune responses, including a decline in natural killer (NK) cells, macrophages, and granulocytes, as well as shifts in cytokine profiles and reduced humoral responsiveness. Melatonin, known to decrease with age, shows potential in stimulating the production of immune cells like granulocytes-macrophages, NK cells, and CD4+ cells, while inhibiting CD8+ cells. Its immunomodulatory effects, acting on the immune-opioid network, G protein-cAMP signal pathway, and intracellular glutathione levels, suggest that melatonin could enhance immune function in the elderly and immunocompromised individuals.
For more details: https://pubmed.ncbi.nlm.nih.gov/16316470/
Carrillo-Vico A, Lardone PJ, Alvarez-Sánchez N, Rodríguez-Rodríguez A, Guerrero JM. Melatonin: buffering the immune system. Int J Mol Sci. 2013;14(4):8638-8683. Published 2013 Apr 22. doi:10.3390/ijms14048638.
Melatonin: buffering the immune system
The 2013 study “Melatonin: buffering the immune system” by Carrillo-Vico A, et al., reviews the diverse and complex roles of melatonin in modulating the immune system. The study acknowledges that while melatonin is recognized as an immunomodulatory compound, the exact mechanisms of how it regulates immunity remain unclear. Some research suggests melatonin acts as an immunostimulant, while other studies highlight its anti-inflammatory properties. The paper supports the concept of melatonin as an immune buffer, stimulating the immune system under basal or immunosuppressed conditions, and acting as an anti-inflammatory agent in the presence of exaggerated immune responses, such as acute inflammation. This study also discusses the clinical significance of melatonin’s various functions in different immune scenarios, including infection, autoimmunity, vaccination, and immunosenescence.
For more details: https://pubmed.ncbi.nlm.nih.gov/23609496/
Melatonin: buffering the immune system
The 2013 study “Melatonin: buffering the immune system” by Carrillo-Vico A, et al., reviews the diverse and complex roles of melatonin in modulating the immune system. The study acknowledges that while melatonin is recognized as an immunomodulatory compound, the exact mechanisms of how it regulates immunity remain unclear. Some research suggests melatonin acts as an immunostimulant, while other studies highlight its anti-inflammatory properties. The paper supports the concept of melatonin as an immune buffer, stimulating the immune system under basal or immunosuppressed conditions, and acting as an anti-inflammatory agent in the presence of exaggerated immune responses, such as acute inflammation. This study also discusses the clinical significance of melatonin’s various functions in different immune scenarios, including infection, autoimmunity, vaccination, and immunosenescence.
For more details: https://pubmed.ncbi.nlm.nih.gov/23609496/
Available at https://www.sciencedirect.com/science/article/pii/S1756464619302452.
The referenced article explores the potential anti-influenza properties of melatonin. It discusses a study where melatonin administration in mice with influenza resulted in reduced leukocyte infiltration in the lungs compared to untreated mice. This suggests a potential role for melatonin in mitigating the inflammatory response associated with influenza infection.
For more details: https://www.sciencedirect.com/science/article/pii/S1756464619302452
Bahrampour Juybari K, Pourhanifeh MH, Hosseinzadeh A, Hemati K, Mehrzadi S. Melatonin potentials against viral infections including COVID-19: Current evidence and new findings. Virus Res. 2020;287:198108. doi:10.1016/j.virusres.2020.198108.
Melatonin potentials against viral infections including COVID-19: Current evidence and new findings. Virus Res
Study “Melatonin potentials against viral infections including COVID-19: Current evidence and new findings” by Bahrampour Juybari K, Pourhanifeh MH, Hosseinzadeh A, Hemati K, Mehrzadi S, published in Virus Research in 2020, explores the potential of melatonin as a therapeutic agent against various viral infections, including COVID-19.
For more information: https://www.sciencedirect.com/science/article/pii/S0168170220310157
Hadi A, Ghaedi E, Moradi S, Pourmasoumi M, Ghavami A, Kafeshani M. Effects of Melatonin Supplementation On Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Horm Metab Res. 2019 Mar;51(3):157-164. doi: 10.1055/a-0841-6638. Epub 2019 Mar 12. PMID: 30861561.
Effects of Melatonin Supplementation On Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
The 2019 study “Effects of Melatonin Supplementation On Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials” by Hadi A, Ghaedi E, et al., focused on the impact of melatonin on blood pressure. This systematic review and meta-analysis included randomized controlled trials (RCTs) to assess the effect of melatonin on systolic and diastolic blood pressure (SBP and DBP). The analysis of five RCTs showed a significant reduction in both SBP and DBP following melatonin supplementation compared to control treatments. The results considered robust through sensitivity analysis, indicated no evidence of publication bias and supported the beneficial effect of melatonin supplementation on blood pressure regulation.
For more details: https://pubmed.ncbi.nlm.nih.gov/30861561/
Grossman E, Laudon M, Yalcin R, Zengil H, Peleg E, Sharabi Y, Kamari Y, Shen-Orr Z, Zisapel N. Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am J Med. 2006 Oct;119(10):898-902. doi: 10.1016/j.amjmed.2006.02.002. PMID: 17000226.
Melatonin reduces night blood pressure in patients with nocturnal hypertension
The study “Melatonin reduces night blood pressure in patients with nocturnal hypertension” by Grossman E, Laudon M, et al., published in 2006, explored the effect of melatonin on night blood pressure in individuals with nocturnal hypertension. This study was significant in understanding the role of melatonin in regulating blood pressure during the night, particularly for patients who experience elevated blood pressure levels during this period.
For more details: https://pubmed.ncbi.nlm.nih.gov/17000226/
Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vasc Health Risk Manag. 2011;7:577-584. doi:10.2147/VHRM.S24603.
Effect of melatonin on nocturnal blood pressure
The 2011 meta-analysis by Grossman E, Laudon M, Zisapel N titled “Effect of melatonin on nocturnal blood pressure” found that controlled-release melatonin significantly reduces nocturnal blood pressure in patients with hypertension. The study, which included seven trials with 221 participants, showed that while overall melatonin did not significantly impact nocturnal blood pressure, controlled-release melatonin effectively lowered both systolic and diastolic blood pressure. In contrast, fast-release melatonin showed no such effect. The findings suggest that controlled-release melatonin could be a safe and effective addition to antihypertensive therapy for nocturnal hypertension.
For more detailed information: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195193/
Możdżan M, Możdżan M, Chałubiński M, Wojdan K, Broncel M. The effect of melatonin on circadian blood pressure in patients with type 2 diabetes and essential hypertension. Arch Med Sci. 2014;10(4):669-675. doi:10.5114/aoms.2014.44858.
The study “The effect of melatonin on circadian blood pressure in patients with type 2 diabetes and essential hypertension” by Możdżan M, Możdżan M, et al., published in 2014, investigated the impact of melatonin on blood pressure in patients with essential hypertension and type 2 diabetes. The study, lasting 8 weeks, involved patients using a 24-hour ambulatory blood pressure monitor and taking melatonin (3 mg per day for the first 4 weeks, followed by 5 mg per day for the next 4 weeks).
The patients were divided into four groups, including dippers (normal night-time blood pressure drop), non-dippers treated with melatonin, and two control groups (dippers and non-dippers without melatonin treatment). The results indicated that 29.5% of non-dippers treated with 3 mg of melatonin daily showed features of dippers, and 32.4% of non-dippers achieved normal diurnal blood pressure rhythm with 5 mg of melatonin per day. Significant decreases in nocturnal systolic, diastolic, and mean blood pressure were observed in non-dippers treated with melatonin.
The study concluded that more than 30% of non-dippers with type 2 diabetes treated with melatonin were restored to the normal circadian rhythm of blood pressure, with the effect being significant for non-dippers only. This indicated that melatonin could be beneficial in regulating nocturnal blood pressure in this patient group.
For more details: https://pubmed.ncbi.nlm.nih.gov/25276149/
Simko F, Paulis L. Melatonin as a potential antihypertensive treatment. J Pineal Res. 2007 Apr;42(4):319-22. doi: 10.1111/j.1600-079X.2007.00436.x. PMID: 17439547.
Melatonin as a potential antihypertensive treatment
The 2007 study “Melatonin as a potential antihypertensive treatment” by Simko F, Paulis L, discusses the potential of melatonin in managing hypertension, a condition that is not well-controlled worldwide. The study found that the nighttime production of melatonin is reduced in individuals with hypertension. Administration of melatonin led to a decrease in blood pressure in various animal models of hypertension, as well as in healthy individuals and patients with arterial hypertension. The most notable results were observed in patients with non-dipping nighttime pressure, where the circadian rhythm of blood pressure variation is disturbed.
The study considers several mechanisms through which melatonin may reduce blood pressure. These include its role as a scavenger and antioxidant, which improves endothelial function and increases the availability of nitric oxide, leading to vasodilatory and hypotensive effects. Melatonin is also thought to affect both the peripheral and central autonomic systems, decreasing the tone of the adrenergic system and increasing that of the cholinergic system. Additionally, melatonin may act on blood pressure through specific melatonin receptors in peripheral vessels or parts of the central nervous system involved in blood pressure control.
The study suggests that further large clinical trials using melatonin in hypertension treatment could answer important questions regarding the optimal dose and regimen of melatonin, the selection of patients who could benefit most from its use, the potential anti-remodeling effect of melatonin, and its interaction with other antihypertensive drugs.
For more details: https://pubmed.ncbi.nlm.nih.gov/17439547/
Peck JS, LeGoff DB, Ahmed I, Goebert D. Cognitive effects of exogenous melatonin administration in elderly persons: a pilot study. Am J Geriatr Psychiatry. 2004 Jul-Aug;12(4):432-6. doi: 10.1176/appi.ajgp.12.4.432. PMID: 15249281.
Cognitive effects of exogenous melatonin administration in elderly persons
The 2004 pilot study “Cognitive effects of exogenous melatonin administration in elderly persons” by Peck JS, LeGoff DB, et al., aimed to assess the impact of exogenous melatonin on cognitive functioning in healthy elderly subjects. This double-blind, placebo-controlled study involved 26 healthy elderly individuals who received either 1 mg of melatonin or a placebo nightly for four weeks. Participants completed a sleep questionnaire and underwent a series of cognitive tests at the beginning and end of the study.
The study found that melatonin administration improved reported morning restedness and sleep latency after nocturnal awakening. It also showed improvements in scores on the California Verbal Learning Test-interference subtest. These results suggest that a nightly dose of 1 mg of melatonin may be effective in enhancing certain aspects of cognitive functioning and subjective sleep quality in elderly subjects. The study indicated the potential of melatonin as a therapeutic agent in treating age-related cognitive decline.
For more detailed information, you can access the full article here: https://pubmed.ncbi.nlm.nih.gov/15249281/
Obayashi K, Saeki K, Iwamoto J, Tone N, Tanaka K, Kataoka H, Morikawa M, Kurumatani N. Physiological Levels of Melatonin Relate to Cognitive Function and Depressive Symptoms: The HEIJO-KYO Cohort. J Clin Endocrinol Metab. 2015 Aug;100(8):3090-6. doi: 10.1210/jc.2015-1859. Epub 2015 Jun 8. PMID: 26052727.
Physiological Levels of Melatonin Relate to Cognitive Function and Depressive Symptoms
The 2015 study “Physiological Levels of Melatonin Relate to Cognitive Function and Depressive Symptoms: The HEIJO-KYO Cohort” by Obayashi K, Saeki K, et al., examined the relationship between melatonin levels and cognitive function and depressive symptoms in elderly individuals. The study, involving a cohort of 1105 community-dwelling elderly individuals, measured urinary 6-sulfatoxymelatonin excretion (UME), Mini-Mental State Examination (MMSE), and Geriatric Depression Scale (GDS) scores.
The results indicated that with higher levels of UME, there was a significant decrease in the prevalence of cognitive impairment (as indicated by MMSE scores) and depressed mood (as indicated by GDS scores). Higher UME levels were significantly associated with lower odds ratios for cognitive impairment and depressed mood, even after adjusting for confounders like age, gender, socioeconomic status, physical activity, and sleep/wake cycles. Notably, the highest UME group showed a significantly lower odds ratio for depressed mood compared to the lowest UME group. The association between physiological melatonin levels and cognitive function was found to be independent of depressive symptoms.
These findings suggest that higher physiological melatonin levels are associated with a lower prevalence of cognitive impairment and depressed mood in a large general elderly population.
For more detailed information, you can access the full article here: https://pubmed.ncbi.nlm.nih.gov/26052727/
Jean-Louis G, von Gizycki H, Zizi F. Melatonin effects on sleep, mood, and cognition in elderly with mild cognitive impairment. J Pineal Res. 1998 Oct;25(3):177-83. doi: 10.1111/j.1600-079x.1998.tb00557.x. PMID: 9745987.
Melatonin effects on sleep, mood, and cognition in elderly with mild cognitive impairment
The 1998 study “Melatonin effects on sleep, mood, and cognition in elderly with mild cognitive impairment” by Jean-Louis G, von Gizycki H, and Zizi F, investigated the impact of immediate-release melatonin on circadian rest-activity profiles, cognition, and mood in elderly individuals with self-reported sleep-wake disturbances. The study involved administering 6 mg of melatonin two hours before the habitual bedtime to ten elderly participants. The findings revealed that melatonin enhanced the rest-activity rhythm and improved sleep quality, as evidenced by a reduction in sleep onset latency and the number of transitions from sleep to wakefulness. However, there was no significant increase in total sleep time or significant reduction in wakefulness during sleep.
Importantly, the study noted improvements in the ability to remember previously learned items and a significant reduction in depressed moods. No side effects or contraindications were reported by any participants during the 10-day trials. These results suggest that melatonin can safely improve certain aspects of sleep, memory, and mood in the elderly over short-term use.
For more detailed information, you can access the full article here: https://pubmed.ncbi.nlm.nih.gov/9745987/
Brusco LI, Márquez M, Cardinali DP. Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer’s disease. Neuro Endocrinol Lett. 2000;21(1):39-42. PMID: 11455329.
The study “Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer’s disease” by Brusco LI, Márquez M, Cardinali DP, conducted in 2000, examined the efficacy of melatonin in treating sleep and cognitive disorders associated with Alzheimer’s disease. It included 14 patients (average age 72) who received 9 mg of melatonin daily for 22 to 35 months. Sleep quality was assessed through sleep logs, while neuropsychological evaluation involved various assessment scales.
The results showed significant improvement in sleep quality for all participants. Importantly, there were no significant changes in cognitive and behavioral symptoms of Alzheimer’s disease during the melatonin treatment period. Sundowning symptoms disappeared in 12 patients and were attenuated in 2. The study concludes that melatonin could be beneficial in treating Alzheimer’s disease, particularly in stabilizing sleep and cognitive symptoms.
For more detailed information, you can access the full article here: https://pubmed.ncbi.nlm.nih.gov/11455329/
Lieberman HR, Waldhauser F, Garfield G, Lynch HJ, Wurtman RJ. Effects of melatonin on human mood and performance. Brain Res. 1984 Dec 10;323(2):201-7. doi: 10.1016/0006-8993(84)90290-7. PMID: 6525511.
Effects of melatonin on human mood and performance. Brain Res.
The 1984 study “Effects of melatonin on human mood and performance” by Lieberman HR, Waldhauser F, et al., explored the behavioral effects of pharmacologic doses of melatonin in humans. Administered acutely to 14 healthy men, the study assessed their mood, performance, memory, and visual sensitivity. Melatonin significantly decreased self-reported alertness and increased sleepiness, as measured by mood questionnaires. It also affected performance by slowing choice-reaction time while decreasing errors of commission. However, sustained fine motor performance, memory, and visual sensitivity were not impaired. The study concluded that pharmacological quantities of melatonin have significant but short-acting sedative-like properties.
For more details: https://pubmed.ncbi.nlm.nih.gov/6525511/
Castaño MY, Garrido M, Rodríguez AB, Gómez MÁ. Melatonin Improves Mood Status and Quality of Life and Decreases Cortisol Levels in Fibromyalgia. Biol Res Nurs. 2019 Jan;21(1):22-29. doi: 10.1177/1099800418811634. Epub 2018 Nov 11. PMID: 30415563.
Melatonin Improves Mood Status and Quality of Life and Decreases Cortisol Levels in Fibromyalgia. Biol Res Nurs
The 2019 study “Melatonin Improves Mood Status and Quality of Life and Decreases Cortisol Levels in Fibromyalgia” by Castaño MY, Garrido M, et al., examined the impact of different doses of melatonin on various health aspects in patients with fibromyalgia. The study involved a period of melatonin administration with varying doses for 10 consecutive days, along with the use of placebo either before or between melatonin doses. Assessments were made using several tools including the Fibromyalgia Impact Questionnaire (FIQ), Numerical Pain Scale (NPS), State-Trait Anxiety Test (STAI), Visual Analog Scale (VAS), and the Short Form-36 Health Survey (SF-36). Additionally, urinary cortisol levels were measured.
The results indicated that melatonin doses of 9, 12, and 15 mg were associated with decreases in total FIQ score, NPS scores, and urinary cortisol levels. After the 12 mg dose of melatonin, there was an improvement in the State-Anxiety subscale of the STAI. The VAS scores improved after the 9 mg dose of melatonin. Furthermore, the dimensions evaluated in the SF-36 questionnaire showed improvement after the 9 mg dose.
The study concluded that melatonin administration could improve mood, reduce anxiety levels, enhance quality of life, and decrease cortisol levels in patients with fibromyalgia.
For more detailed information, you can access the full article here: https://pubmed.ncbi.nlm.nih.gov/30415563/
Boyce P, Hopwood M. Manipulating melatonin in managing mood. Acta Psychiatr Scand Suppl. 2013;(444):16-23. doi: 10.1111/acps.12175. Erratum in: Acta Psychiatr Scand Suppl. 2014 Sep;130(3):240. PMID: 23909693.
Manipulating melatonin in managing mood. Acta Psychiatr Scand Suppl
The study “Manipulating melatonin in managing mood” by Boyce P, Hopwood M, published in 2013, explored the relationship between circadian rhythms and major depression, suggesting that disruptions in these rhythms may be a key mechanism in the disorder. The study reviewed various strategies for resynchronizing circadian rhythms as a potential treatment approach, with a focus on manipulating melatonin secretion. Melatonin, a hormone secreted primarily at night, is a stable marker of circadian rhythms, and its timing can be altered through various means, including exogenous melatonin, specific melatonin receptor agonists, light exposure, and sleep deprivation.
The review included an analysis of studies that examined the antidepressant effects of exogenous melatonin, light therapy, sleep deprivation, and melatonin receptor agonists. It was found that bright light therapy, particularly for seasonal affective disorder, and sleep deprivation (though its effect is time-limited) showed antidepressant effects. Agomelatine, a novel antidepressant with agonistic properties for melatonin receptors MT1 and MT2 and antagonism of the 5HT2c receptor, also demonstrated antidepressant effects. However, the role of melatonin itself as an antidepressant was not definitively demonstrated in the review.
For more details: https://pubmed.ncbi.nlm.nih.gov/23909693/
Chojnacki C, Walecka-Kapica E, Klupinska G, Pawlowicz M, Blonska A, Chojnacki J. Effects of fluoxetine and melatonin on mood, sleep quality and body mass index in postmenopausal women. J Physiol Pharmacol. 2015 Oct;66(5):665-71. PMID: 26579572.
Effects of fluoxetine and melatonin on mood, sleep quality and body mass index in postmenopausal women.
The study conducted by Chojnacki et al. investigated the impact of fluoxetine and melatonin on postmenopausal women. The combined administration of fluoxetine and melatonin demonstrated benefits in managing mood, sleep quality, and appetite disorders in this population.
For more details: https://pubmed.ncbi.nlm.nih.gov/26579572/
Liu J, Huang F, He HW. Melatonin effects on hard tissues: bone and tooth. Int J Mol Sci. 2013;14(5):10063-10074. Published 2013 May 10. doi:10.3390/ijms140510063.
Melatonin effects on hard tissues: bone and tooth
The article “Melatonin effects on hard tissues: bone and tooth” from the International Journal of Molecular Sciences, published on May 10, 2013, delves into the role of melatonin in relation to hard tissues such as bones and teeth. Melatonin, an endogenous hormone produced in the pineal gland, is known for its involvement in various physiological processes, including circadian rhythm regulation, blood pressure control, and immune function. This review focuses particularly on the recent research and applications of melatonin in bone and tooth health. The article discusses how melatonin has been studied in the context of bone remodeling, osteoporosis, the integration of dental implants, and dentine formation, highlighting the growing interest and significant findings in these areas.
For more information: https://pubmed.ncbi.nlm.nih.gov/23665905/
Muñoz F, López-Peña M, Miño N, Gómez-Moreno G, Guardia J, Cutando A. Topical application of melatonin and growth hormone accelerates bone healing around dental implants in dogs. Clin Implant Dent Relat Res. 2012 Apr;14(2):226-35. doi: 10.1111/j.1708-8208.2009.00242.x. Epub 2009 Sep 29. PMID: 19793331.
Topical application of melatonin and growth hormone accelerates bone healing around dental implants in dogs
The study “Topical application of melatonin and growth hormone accelerates bone healing around dental implants in dogs,” conducted by Muñoz F, López-Peña M, Miño N, and others, was published in the Clinical Implant Dentistry and Related Research journal in April 2012. This research explores the effects of topical application of melatonin and growth hormone on bone healing around dental implants in dogs. The findings suggest that these substances may have a positive impact on accelerating the bone healing process, a significant consideration in the field of dental implantology. The study represents an important contribution to understanding how hormonal treatments can potentially enhance the success and speed of dental implant integration.
For more details: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1708-8208.2009.00242.x
Available at https://www.frontiersin.org/articles/10.3389/fphar.2020.00667/full.
Yi C, Pan X, Yan H, Guo M, Pierpaoli W. Effects of melatonin in age-related macular degeneration. Ann N Y Acad Sci. 2005 Dec;1057:384-92. doi: 10.1196/annals.1356.029. PMID: 16399908.
Effects of melatonin in age-related macular degeneration
The study titled “Effects of melatonin in age-related macular degeneration” by Yi C, Pan X, Yan H, Guo M, Pierpaoli W, published in the Annals of the New York Academy of Sciences in December 2005, investigates the potential therapeutic role of melatonin in treating age-related macular degeneration (AMD). This research is crucial as AMD is a significant cause of vision loss in the elderly. The study’s findings contribute significantly to understanding how melatonin, renowned for its antioxidant properties, may influence or mitigate the progression of AMD.
For a detailed summary and insights, you can refer to: https://doi.org/10.1196/annals.1356.029
Stefanova NA, Zhdankina AA, Fursova AZh, Kolosova NG. [Potential of melatonin for prevention of age-related macular degeneration: experimental study]. Adv Gerontol. 2013;26(1):122-9. Russian. PMID: 24003738.
Potential of melatonin for prevention of age-related macular degeneration: experimental study
The study by Stefanova NA, Zhdankina AA, Fursova AZh, and Kolosova NG, titled “[Potential of melatonin for prevention of age-related macular degeneration: experimental study],” published in the journal ‘Advances in Gerontology’ in 2013, explores the effectiveness of melatonin in preventing age-related macular degeneration (AMD). Conducted in Russian, this research adds to the growing body of evidence regarding the potential therapeutic uses of melatonin, especially in the context of age-related diseases like AMD.
For detailed findings and methodology, you can refer to https://pubmed.ncbi.nlm.nih.gov/24003738/
Blasiak J, Reiter RJ, Kaarniranta K. Melatonin in Retinal Physiology and Pathology: The Case of Age-Related Macular Degeneration. Oxid Med Cell Longev. 2016;2016:6819736. doi: 10.1155/2016/6819736. Epub 2016 Sep 5. PMID: 27688828; PMCID: PMC5027321.
Melatonin in Retinal Physiology and Pathology: The Case of Age-Related Macular Degeneration
The article by Blasiak J, Reiter RJ, and Kaarniranta K, titled “Melatonin in Retinal Physiology and Pathology: The Case of Age-Related Macular Degeneration,” published in the journal ‘Oxidative Medicine and Cellular Longevity’ in 2016, examines the role of melatonin in the context of retinal health, particularly focusing on age-related macular degeneration (AMD). This study highlights the potential of melatonin in the physiology and pathology of the retina, suggesting its significance in understanding and potentially managing AMD.
For comprehensive insights, visit at https://doi.org/10.1155/2016/6819736
Rastmanesh R. Potential of melatonin to treat or prevent age-related macular degeneration through stimulation of telomerase activity. Med Hypotheses. 2011 Jan;76(1):79-85. doi: 10.1016/j.mehy.2010.08.036. Epub 2010 Sep 29. PMID: 20884126.
Potential of melatonin to treat or prevent age-related macular degeneration through stimulation of telomerase activity
The paper by Rastmanesh R., titled “Potential of melatonin to treat or prevent age-related macular degeneration through stimulation of telomerase activity,” published in ‘Medical Hypotheses’ in January 2011, discusses the possibility of using melatonin as a treatment or preventative measure for age-related macular degeneration (AMD). This hypothesis is based on melatonin’s potential ability to stimulate telomerase activity, which could be beneficial in addressing the cellular aging processes that contribute to AMD.
For a detailed exploration of this hypothesis, refer to the article using: https://doi.org/10.1016/j.mehy.2010.08.036
Lundmark PO, Pandi-Perumal SR, Srinivasan V, Cardinali DP. Role of melatonin in the eye and ocular dysfunctions. Vis Neurosci. 2006 Nov-Dec;23(6):853-62. doi: 10.1017/S0952523806230189. PMID: 17266777.
Role of melatonin in the eye and ocular dysfunctions
The article “Role of melatonin in the eye and ocular dysfunctions” by Lundmark PO, Pandi-Perumal SR, Srinivasan V, Cardinali DP, published in the journal ‘Visual Neuroscience’ in 2006, examines the influence of melatonin on various aspects of eye health and its potential implications in ocular disorders. This research provides insight into how melatonin, a hormone known for regulating sleep-wake cycles, may also play a significant role in the functioning and health of the eye, potentially affecting various ocular diseases.
For more details: https://doi.org/10.1017/S0952523806230189
Tosini G, Baba K, Hwang CK, Iuvone PM. Melatonin: an underappreciated player in retinal physiology and pathophysiology. Exp Eye Res. 2012;103:82-89. doi:10.1016/j.exer.2012.08.009.
Melatonin: an underappreciated player in retinal physiology and pathophysiology
The study “Melatonin: an underappreciated player in retinal physiology and pathophysiology” by Tosini G, Baba K, Hwang CK, Iuvone PM, published in Experimental Eye Research in 2012, explores the significant yet often overlooked role of melatonin in retinal health. This research delves into how melatonin, commonly known for its influence on sleep, also impacts various aspects of retinal physiology and potentially plays a role in the development or progression of certain retinal diseases
For more details: https://doi.org/10.1016/j.exer.2012.08.009
Kleszczynski K, Fischer TW. Melatonin and human skin aging. Dermatoendocrinol. 2012 Jul 1;4(3):245-52. doi: 10.4161/derm.22344. PMID: 23467217; PMCID: PMC3583885.
Melatonin and human skin aging. Dermatoendocrinol
The article “Melatonin and human skin aging” by Kleszczynski K and Fischer TW, published in Dermato-Endocrinology in 2012, investigates the impact of melatonin on human skin aging. This study explores the potential protective or beneficial effects of melatonin, a hormone recognized for its antioxidant properties, on skin health and the aging process. The research could provide insights into how melatonin influences skin physiology and its possible use in anti-aging treatments.
For more details visit at https://doi.org/10.4161/derm.22344
Rusanova I, Martínez-Ruiz L, Florido J, et al. Protective Effects of Melatonin on the Skin: Future Perspectives. Int J Mol Sci. 2019;20(19):4948. Published 2019 Oct 8. doi:10.3390/ijms20194948.
Protective Effects of Melatonin on the Skin: Future Perspectives
The paper “Protective Effects of Melatonin on the Skin: Future Perspectives” by Rusanova I, Martínez-Ruiz L, Florido J, et al., published in the International Journal of Molecular Sciences in 2019, discusses the beneficial impacts of melatonin on skin health. It focuses on elucidating the protective roles of melatonin against a spectrum of skin disorders, considering its antioxidant properties and effects on skin regeneration and aging. This research provides insights into the potential applications of melatonin in dermatology and skincare.
For more details, visit https://doi.org/10.3390/ijms20194948
Day D, Burgess CM, Kircik LH. Assessing the Potential Role for Topical Melatonin in an Antiaging Skin Regimen. J Drugs Dermatol. 2018 Sep 1;17(9):966-969. PMID: 30235383.
The article “Assessing the Potential Role for Topical Melatonin in an Antiaging Skin Regimen” by Day D, Burgess CM, Kircik LH, published in the Journal of Drugs in Dermatology in September 2018, examines the potential benefits of using topical melatonin as part of an anti-aging skin care regimen. This study explores how melatonin, when applied topically, may affect skin aging, considering its antioxidant properties and other beneficial effects on skin health. The research contributes to the understanding of melatonin’s role in dermatological applications, particularly in anti-aging skin treatments.
For more details: https://pubmed.ncbi.nlm.nih.gov/30235383/
Eşrefoğlu M, Seyhan M, Gül M, Parlakpinar H, Batçioğlu K, Uyumlu B. Potent therapeutic effect of melatonin on aging skin in pinealectomized rats. J Pineal Res. 2005 Oct;39(3):231-7. doi: 10.1111/j.1600-079X.2005.00235.x. PMID: 16150102.
Potent therapeutic effect of melatonin on aging skin in pinealectomized rats
The study “Potent therapeutic effect of melatonin on aging skin in pinealectomized rats” by Eşrefoğlu M, Seyhan M, Gül M, and others, published in the Journal of Pineal Research in October 2005, investigates the effects of melatonin on aging skin using pinealectomized rats as a model. This research explores the potential of melatonin as a therapeutic agent for combating signs of skin aging, focusing on its impact in an animal model where natural melatonin production is disrupted.
For more details, you can visit https://doi.org/10.1111/j.1600-079X.2005.00235.x
Nanzadsuren T, Myatav T, Dorjkhuu A, Byamba K. Association between serum melatonin and skin aging in an urban population of Mongolia. J Cosmet Dermatol. 2020 Jun;19(6):1501-1507. doi: 10.1111/jocd.13166. Epub 2019 Sep 30. PMID: 31566872.
Association between serum melatonin and skin aging in an urban population of Mongolia
The study “Association between serum melatonin and skin aging in an urban population of Mongolia” by Nanzadsuren T, Myatav T, Dorjkhuu A, Byamba K, published in the Journal of Cosmetic Dermatology in June 2020, explores the relationship between serum melatonin levels and skin aging in an urban Mongolian population. This research investigates how melatonin, a hormone known for its role in regulating circadian rhythms and antioxidant properties, correlates with the signs and process of skin aging in humans.
For more details: https://doi.org/10.1111/jocd.13166
Dong K, Goyarts E, Rella A, Pelle E, Wong YH, Pernodet N. Age Associated Decrease of MT-1 Melatonin Receptor in Human Dermal Skin Fibroblasts Impairs Protection Against UV-Induced DNA Damage. Int J Mol Sci. 2020 Jan 3;21(1):326. doi: 10.3390/ijms21010326. PMID: 31947744; PMCID: PMC6982064.
Age Associated Decrease of MT-1 Melatonin Receptor in Human Dermal Skin Fibroblasts Impairs Protection Against UV-Induced DNA Damage
The article “Age Associated Decrease of MT-1 Melatonin Receptor in Human Dermal Skin Fibroblasts Impairs Protection Against UV-Induced DNA Damage,” by Dong K, Goyarts E, Rella A, and others, published in the International Journal of Molecular Sciences in January 2020, examines how aging affects the MT-1 melatonin receptor in human skin fibroblasts and its impact on DNA damage from UV exposure. This study highlights the reduced ability of aging skin cells to protect against UV-induced DNA damage, attributed to decreased melatonin receptor activity.
For more details: https://doi.org/10.3390/ijms21010326
Milani M, Sparavigna A. Antiaging efficacy of melatonin-based day and night creams: a randomized, split-face, assessor-blinded proof-of-concept trial. Clin Cosmet Investig Dermatol. 2018 Jan 24;11:51-57. doi: 10.2147/CCID.S153905. PMID: 29416368; PMCID: PMC5788993.
Antiaging efficacy of melatonin-based day and night creams: a randomized, split-face, assessor-blinded proof-of-concept trial
The study “Antiaging efficacy of melatonin-based day and night creams: a randomized, split-face, assessor-blinded proof-of-concept trial” by Milani M and Sparavigna A, published in Clinical, Cosmetic and Investigational Dermatology in 2018, focuses on the effectiveness of day and night creams containing melatonin in anti-aging skin treatment. This randomized, split-face, assessor-blinded trial evaluates the impact of these melatonin-based creams on skin aging signs. For a comprehensive understanding of the study results and methodology.
you can access the article using https://doi.org/10.2147/CCID.S153905
Available at https://link.springer.com/article/10.1007/s13555-020-00443-2.
Song R, Ren L, Ma H, Hu R, Gao H, Wang L, Chen X, Zhao Z, Liu J. Melatonin promotes diabetic wound healing in vitro by regulating keratinocyte activity. Am J Transl Res. 2016 Nov 15;8(11):4682-4693. PMID: 27904671; PMCID: PMC5126313.
The study “Melatonin promotes diabetic wound healing in vitro by regulating keratinocyte activity” by Song R, Ren L, Ma H, and others, published in the American Journal of Translational Research in 2016, investigates the role of melatonin in enhancing diabetic wound healing. This research focuses on how melatonin affects keratinocyte activity, which is crucial in the wound healing process, particularly in the context of diabetes. The findings contribute to understanding melatonin’s potential therapeutic application in diabetic wound management.
For more detailed information, you can refer to the article using https://pubmed.ncbi.nlm.nih.gov/27904671/
Soybir G, Topuzlu C, Odabaş O, Dolay K, Bilir A, Köksoy F. The effects of melatonin on angiogenesis and wound healing. Surg Today. 2003;33(12):896-901. doi: 10.1007/s00595-003-2621-3. PMID: 14669079.
The effects of melatonin on angiogenesis and wound healing
The study “The effects of melatonin on angiogenesis and wound healing” by Soybir G, Topuzlu C, Odabaş O, and others, published in ‘Surgery Today’ in 2003, explores the impact of melatonin on wound healing and the process of angiogenesis, which is the formation of new blood vessels. This research potentially provides insights into how melatonin could influence the body’s healing process and vascular growth in wound sites.
For more detailed information: https://doi.org/10.1007/s00595-003-2621-3
Available at https://onlinelibrary.wiley.com/doi/10.1111/j.1600-079X.2007.00541.x.
Jin, H., Zhang, Z., Wang, C. et al. Melatonin protects endothelial progenitor cells against AGE-induced apoptosis via autophagy flux stimulation and promotes wound healing in diabetic mice. Exp Mol Med 50, 1–15 (2018). https://doi.org/10.1038/s12276-018-0177-z.
Melatonin protects endothelial progenitor cells against AGE-induced apoptosis via autophagy flux stimulation and promotes wound healing in diabetic mice
The study “Melatonin protects endothelial progenitor cells against AGE-induced apoptosis via autophagy flux stimulation and promotes wound healing in diabetic mice” by Jin H., Zhang Z., Wang C., et al., published in Experimental & Molecular Medicine in 2018, examines the protective role of melatonin on endothelial progenitor cells (EPCs) against apoptosis (cell death) induced by Advanced Glycation End-products (AGEs). The study also assesses how melatonin aids wound healing in diabetic mice, primarily through stimulating autophagy flux.
For more detailed information: https://doi.org/10.1038/s12276-018-0177-z
Magierowski M, Jasnos K, Brzozowska I, Drozdowicz D, Sliwowski Z, Nawrot E, Szczyrk U, Kwiecień S. Melatonina jako czynnik leczniczy wzgledem wrzodów zoładka w warunkach eksperymentalnej cukrzycy [Melatonin as a therapeutic factor in gastric ulcer healing under experimental diabetes]. Przegl Lek. 2013;70(11):942-6. Polish. PMID: 24697035.
Melatonina jako czynnik leczniczy względem wrzodów żołądka w warunkach eksperymentalnej cukrzycy
The study “Melatonina jako czynnik leczniczy względem wrzodów żołądka w warunkach eksperymentalnej cukrzycy” (Melatonin as a therapeutic factor in gastric ulcer healing under experimental diabetes) by Magierowski M, Jasnos K, Brzozowska I, and others, published in ‘Przegląd Lekarski’ in 2013, explores the therapeutic effects of melatonin in the healing of gastric ulcers, specifically under conditions of experimental diabetes. This research investigates how melatonin influences the healing process of gastric ulcers in diabetic environments.
For the full article you can visit https://pubmed.ncbi.nlm.nih.gov/24697035/
Pourhanifeh, M.H., Hosseinzadeh, A., Dehdashtian, E. et al. Melatonin: new insights on its therapeutic properties in diabetic complications. Diabetol Metab Syndr 12, 30 (2020). https://doi.org/10.1186/s13098-020-00537-z.
Melatonin: new insights on its therapeutic properties in diabetic complications
The article “Melatonin: new insights on its therapeutic properties in diabetic complications” by Pourhanifeh M.H., Hosseinzadeh A., Dehdashtian E., et al., published in Diabetology & Metabolic Syndrome in 2020, offers a comprehensive look at how melatonin can be beneficial in managing complications associated with diabetes. This study delves into various aspects of diabetic complications and explores how the properties of melatonin might alleviate these conditions.
For an in-depth understanding you can visit https://doi.org/10.1186/s13098-020-00537-z
Sharma S, Singh H, Ahmad N, Mishra P, Tiwari A. The role of melatonin in diabetes: therapeutic implications. Arch Endocrinol Metab. 2015 Oct;59(5):391-9. doi: 10.1590/2359-3997000000098. Epub 2015 Aug 28. PMID: 26331226.
The role of melatonin in diabetes: therapeutic implications
The article “The role of melatonin in diabetes: therapeutic implications” by Sharma S, Singh H, Ahmad N, Mishra P, Tiwari A, published in Archives of Endocrinology and Metabolism in October 2015, discusses the potential therapeutic role of melatonin in diabetes management. This study examines how melatonin, acknowledged for its role in regulating circadian rhythms, could potentially influence diabetes treatment and management strategies.
For detailed insights on this study: https://doi.org/10.1590/2359-3997000000098
Doosti-Irani A, Ostadmohammadi V, Mirhosseini N, Mansournia MA, Reiter RJ, Kashanian M, Rahimi M, Razavi M, Asemi Z. The Effects of Melatonin Supplementation on Glycemic Control: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Horm Metab Res. 2018 Nov;50(11):783-790. doi: 10.1055/a-0752-8462. Epub 2018 Nov 5. Erratum in: Horm Metab Res. 2018 Nov;50(11):e6. PMID: 30396207.
The Effects of Melatonin Supplementation on Glycemic Control
The systematic review and meta-analysis “The Effects of Melatonin Supplementation on Glycemic Control” by Doosti-Irani A, Ostadmohammadi V, Mirhosseini N, and others, published in Hormone and Metabolic Research in November 2018, evaluates the impact of melatonin supplementation on glycemic control. This study compiles and analyzes data from various randomized controlled trials to ascertain how melatonin supplementation influences blood sugar levels.
For a comprehensive understanding of the findings and their implications in glycemic management, you can refer to the article using: https://doi.org/10.1055/a-0752-8462
Mok JX, Ooi JH, Ng KY, Koh RY, Chye SM. A new perspective on the role of melatonin in diabetes and its complications. Horm Mol Biol Clin Investig. 2019 Nov 6;40(1):/j/hmbci.2019.40.issue-1/hmbci-2019-0036/hmbci-2019-0036.xml. doi: 10.1515/hmbci-2019-0036. PMID: 31693492.
A new perspective on the role of melatonin in diabetes and its complications
The article “A new perspective on the role of melatonin in diabetes and its complications” by Mok JX, Ooi JH, Ng KY, and others, published in Hormone Molecular Biology and Clinical Investigation in November 2019, offers insights into how melatonin could play a significant role in diabetes and related complications. This study discusses the multifaceted effects of melatonin within the context of diabetes, potentially covering aspects such as glucose metabolism, insulin sensitivity, and diabetic complications.
For more details, visit at https://doi.org/10.1515/hmbci-2019-0036
McMullan CJ, Schernhammer ES, Rimm EB, Hu FB, Forman JP. Melatonin secretion and the incidence of type 2 diabetes. JAMA. 2013 Apr 3;309(13):1388-96. doi: 10.1001/jama.2013.2710. PMID: 23549584; PMCID: PMC3804914.
Melatonin secretion and the incidence of type 2 diabetes
The study “Melatonin secretion and the incidence of type 2 diabetes” by McMullan CJ, Schernhammer ES, Rimm EB, and others, published in JAMA in April 2013, investigates the relationship between melatonin secretion and the risk of developing type 2 diabetes. This research assesses how fluctuations in melatonin levels could influence the likelihood of onset of type 2 diabetes.
For in-depth information https://doi.org/10.1001/jama.2013.2710
Espino J, Rodríguez AB, Pariente JA. Melatonin and Oxidative Stress in the Diabetic State: Clinical Implications and Potential Therapeutic Applications. Curr Med Chem. 2019;26(22):4178-4190. doi: 10.2174/0929867325666180410094149. PMID: 29637854.
Melatonin and Oxidative Stress in the Diabetic State: Clinical Implications and Potential Therapeutic Applications
The study “Melatonin and Oxidative Stress in the Diabetic State: Clinical Implications and Potential Therapeutic Applications” by Espino J, Rodríguez AB, Pariente JA, published in Current Medicinal Chemistry in 2019, examines the role of melatonin in managing oxidative stress in diabetes. The study discusses the clinical implications and potential therapeutic uses of melatonin in reducing oxidative damage, a key factor in the complications associated with diabetes.
For more information: https://doi.org/10.2174/0929867325666180410094149
Zephy D, Ahmad J. Type 2 diabetes mellitus: Role of melatonin and oxidative stress. Diabetes Metab Syndr. 2015 Apr-Jun;9(2):127-31. doi: 10.1016/j.dsx.2014.09.018. Epub 2014 Oct 29. PMID: 25450812.
Type 2 diabetes mellitus: Role of melatonin and oxidative stress
The article “Type 2 diabetes mellitus: Role of melatonin and oxidative stress” by Zephy D and Ahmad J, published in Diabetes & Metabolic Syndrome in the April-June 2015 issue, focuses on the involvement of melatonin in managing oxidative stress related to type 2 diabetes mellitus. This study explores the relationship between melatonin, a hormone with antioxidant properties, and its impact on oxidative stress, a significant factor in the pathology of type 2 diabetes.
For more information: https://doi.org/10.1016/j.dsx.2014.09.018
At the age of 60, I look and feel better than I ever have in my entire life! Switching my health program and hormone replacement therapy regimen over to Genemedics was one of the best decisions I’ve ever made in my life! Genemedics and Dr George have significantly improved my quality of life and also dramatically improved my overall health. I hav...
Nick Cassavetes ,60 yrs old
Movie Director (“The Notebook”, “John Q”, “Alpha Dog”), Actor and Writer
I am now in my mid-sixties and feel better than I did in my 20’s. Many people have commented that I actually look 20 years younger since I started the program at Genemedics.
Calling Dr. George has proven to be one of the best decisions I have made in my life. Doctors and society convince us that developing various health issues and negative sy...
Pamela Hill ,66 yrs old
Call 800-277-4041 for a Free Consultation
Genemedics® Health Institute is a global premier institute dedicated to revolutionizing health and medicine through healthy lifestyle education, guidance and accountability in harmony with functional medicine. Our physician-supervised health programs are personally customized to help you reach your health and fitness goals while looking and feeling better than ever.
© Copyright Genemedics Health Institute. All Rights Reserved. Privacy Policy.
STEPS AWAY FROM A YOUNGER. HEALTHIER YOU!
Call 800-277-4041 for a Free Consultation
What to expect during your consultation: